The FDA issued a complete response letter to Genentech indicating it cannot approve the company’s biologic license ...

The FDA determined the data from STARGLO did not provide sufficient evidence to support approving glofitamab-gxbm (Columvi) in combination with gemcitabine and oxaliplatin to treat relapsed/refractory ...

The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL ...

During a live event, Matthew Lunning, DO, and participants discussed how identifying primary refractory and early relapsed ...

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

The FDA has loosened safety restrictions for six CAR T-cell immunotherapies, used in treating a number of blood cancers.

It is designed to treat lymphoblastic leukaemia and diffuse large B-cell lymphoma. India’s Kauvery Hospital has announced the launch of its CAR-T cell therapy service for certain blood cancers that do ...

The bispecific antibody market is experiencing rapid growth, primarily driven by the increasing prevalence of complex chronic diseases, such as cance ...

Blinatumomab, a bispecific T-cell engager, has demonstrated substantial clinical benefits in treating pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).

Over the past decade, several novel immunotherapies have transformed the treatment landscape of relapsed or refractory B-cell acute lymphoblastic leukaemia. In the pivotal TOWER trial, blinatumomab—a ...

An agent that may fulfill these requirements is the glycan-binding protein Galectin-9 (Gal-9). Indeed, treatment with Gal-9 reduced total cell counts and cell viability of various B cell NHL cell ...